First in Patient Study for PF-06840003 in Malignant Gliomas
Public ClinicalTrials.gov record NCT02764151. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06840003 IN PATIENTS WITH MALIGNANT GLIOMAS
Study identification
- NCT ID
- NCT02764151
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Pfizer
- Industry
- Enrollment
- 17 participants
Conditions and interventions
Conditions
Interventions
- PF-06840003 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 8, 2016
- Primary completion
- Dec 25, 2018
- Completion
- Dec 25, 2018
- Last update posted
- Jan 26, 2020
2016 – 2018
United States locations
- U.S. sites
- 14
- U.S. states
- 5
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ronald Reagan UCLA Medical Center | Los Angeles | California | 90095-6894 | — |
| UCLA Clinical & Translational Research Center | Los Angeles | California | 90095 | — |
| UCLA Oncology Center | Los Angeles | California | 90095 | — |
| UCLA School of Medicine | Los Angeles | California | 90095 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Brigham & Women's Hospital | Boston | Massachusetts | 02115 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| University of New Mexico Comprehensive Cancer Center | Albuquerque | New Mexico | 87102 | — |
| Columbia University Medical Center | New York | New York | 10019 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| CUMC Research Pharmacy | New York | New York | 10032 | — |
| Columbia Doctors Tarrytown | Tarrytown | New York | 10591 | — |
| Duke Cancer Center | Durham | North Carolina | 27710 | — |
| Duke University Medical Center, Duke Cancer Center | Durham | North Carolina | 27710 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02764151, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 26, 2020 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02764151 live on ClinicalTrials.gov.